You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSpirapril
Accession NumberDB01348
TypeSmall Molecule
GroupsApproved
DescriptionSpirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.
Structure
Thumb
Synonyms
Renormax
Spirapril
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RenormaxNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Spirapril hydrochloride
ThumbNot applicableDBSALT001443
Categories
UNII96U2K78I3V
CAS number83647-97-6
WeightAverage: 466.614
Monoisotopic: 466.15961346
Chemical FormulaC22H30N2O5S2
InChI KeyInChIKey=HRWCVUIFMSZDJS-SZMVWBNQSA-N
InChI
InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
IUPAC Name
(8S)-7-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[[email protected]]1C(O)=O)SCCS2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Aralkylamine
  • Fatty acid ester
  • Dithioketal
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • 1,3-dithiolane
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Dithiolane
  • Thioacetal
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Dialkylthioether
  • Thioether
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationSpirapril is an ACE inhibitor class drug used to treat hypertension.
PharmacodynamicsSpirapril is an angiotensin-converting enzyme (ACE) inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. By blocking ACE, spirapril decreases angiotensin II which is a vasoconstrictor and inducer of aldosterone. So by inhibiting the enzymes, aldosterone secreation is decreased (so less sodium is reabsorbed) and there is a decrease in vasoconstriction. Combined, this leades to a decrease in blood pressure.
Mechanism of actionSpiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
Related Articles
AbsorptionBioavailability is 50% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Converted to spiraprilat following oral administration.

SubstrateEnzymesProduct
Spirapril
Not Available
SpiraprilatDetails
Route of eliminationNot Available
Half life30 to 35 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Spirapril Action PathwayDrug actionSMP00156
Spirapril Metabolism PathwayDrug metabolismSMP00598
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5287
Blood Brain Barrier-0.9614
Caco-2 permeable-0.83
P-glycoprotein substrateSubstrate0.8223
P-glycoprotein inhibitor INon-inhibitor0.6938
P-glycoprotein inhibitor IINon-inhibitor0.7426
Renal organic cation transporterNon-inhibitor0.8836
CYP450 2C9 substrateNon-substrate0.833
CYP450 2D6 substrateNon-substrate0.8553
CYP450 3A4 substrateNon-substrate0.5658
CYP450 1A2 substrateNon-inhibitor0.8439
CYP450 2C9 inhibitorNon-inhibitor0.7259
CYP450 2D6 inhibitorNon-inhibitor0.8813
CYP450 2C19 inhibitorNon-inhibitor0.5956
CYP450 3A4 inhibitorInhibitor0.5073
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6331
Ames testNon AMES toxic0.8764
CarcinogenicityNon-carcinogens0.908
BiodegradationNot ready biodegradable0.9115
Rat acute toxicity2.2396 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Non-inhibitor0.5579
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0293 mg/mLALOGPS
logP1.79ALOGPS
logP1.6ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.62ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity121.94 m3·mol-1ChemAxon
Polarizability48.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, Lacour B, Grunfeld JP: Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S25-7. [PubMed:1382161 ]
  2. Noble S, Sorkin EM: Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66. [PubMed:7601014 ]
  3. Rosendorff C, Patton J, Radford HM, Kalliatakis B: Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S105-9. [PubMed:1382157 ]
  4. Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G: Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. Scand J Urol Nephrol. 1999 Feb;33(1):57-62. [PubMed:10100366 ]
External Links
ATC CodesC09AA11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Spirapril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Spirapril.
AcebutololAcebutolol may increase the hypotensive activities of Spirapril.
AceclofenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Aceclofenac.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Spirapril.
AdapaleneThe risk or severity of adverse effects can be increased when Spirapril is combined with Adapalene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Spirapril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Spirapril.
AliskirenSpirapril may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Spirapril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Spirapril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Spirapril.
AlprenololAlprenolol may increase the hypotensive activities of Spirapril.
AmbrisentanSpirapril may increase the hypotensive activities of Ambrisentan.
AmifostineSpirapril may increase the hypotensive activities of Amifostine.
AmilorideAmiloride may increase the hyperkalemic activities of Spirapril.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Spirapril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Spirapril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Spirapril.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Spirapril.
AmlodipineAmlodipine may increase the hypotensive activities of Spirapril.
AntipyrineThe risk or severity of adverse effects can be increased when Spirapril is combined with Antipyrine.
ApremilastThe risk or severity of adverse effects can be increased when Spirapril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Spirapril.
ArdeparinArdeparin may increase the hyperkalemic activities of Spirapril.
AtenololAtenolol may increase the hypotensive activities of Spirapril.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Spirapril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Spirapril.
AzapropazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Azapropazone.
AzathioprineSpirapril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Spirapril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Spirapril.
BalsalazideThe risk or severity of adverse effects can be increased when Spirapril is combined with Balsalazide.
BemiparinBemiparin may increase the hyperkalemic activities of Spirapril.
BenazeprilBenazepril may increase the hypotensive activities of Spirapril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Spirapril.
BenmoxinBenmoxin may increase the hypotensive activities of Spirapril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Benoxaprofen.
BepridilBepridil may increase the hypotensive activities of Spirapril.
BetaxololBetaxolol may increase the hypotensive activities of Spirapril.
BethanidineBethanidine may increase the hypotensive activities of Spirapril.
BimatoprostBimatoprost may increase the hypotensive activities of Spirapril.
BisoprololBisoprolol may increase the hypotensive activities of Spirapril.
BoceprevirThe serum concentration of Spirapril can be decreased when it is combined with Boceprevir.
BosentanBosentan may increase the hypotensive activities of Spirapril.
BretyliumBretylium may increase the hypotensive activities of Spirapril.
BrimonidineSpirapril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Spirapril.
BromfenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Spirapril.
BumetanideBumetanide may increase the hypotensive activities of Spirapril.
BupranololSpirapril may increase the hypotensive activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Spirapril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Spirapril.
CandesartanCandesartan may increase the hypotensive activities of Spirapril.
CandoxatrilCandoxatril may increase the hypotensive activities of Spirapril.
CaptoprilCaptopril may increase the hypotensive activities of Spirapril.
CarbamazepineThe metabolism of Spirapril can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Spirapril.
CarprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Spirapril.
CarvedilolCarvedilol may increase the hypotensive activities of Spirapril.
CastanospermineThe risk or severity of adverse effects can be increased when Spirapril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Celecoxib.
CeliprololSpirapril may increase the hypotensive activities of Celiprolol.
CertoparinCertoparin may increase the hyperkalemic activities of Spirapril.
ChloroquineThe risk or severity of adverse effects can be increased when Spirapril is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Spirapril.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Spirapril.
CilazaprilCilazapril may increase the hypotensive activities of Spirapril.
CiprofloxacinSpirapril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Spirapril.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Spirapril.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Spirapril.
ClonidineClonidine may increase the hypotensive activities of Spirapril.
ClonixinThe risk or severity of adverse effects can be increased when Spirapril is combined with Clonixin.
CryptenamineCryptenamine may increase the hypotensive activities of Spirapril.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Spirapril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Spirapril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Spirapril.
CyclothiazideCyclothiazide may increase the hypotensive activities of Spirapril.
D-LimoneneThe risk or severity of adverse effects can be increased when Spirapril is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Spirapril.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Spirapril.
DebrisoquinSpirapril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Spirapril.
DeserpidineSpirapril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Spirapril.
DiazoxideDiazoxide may increase the hypotensive activities of Spirapril.
DiclofenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Diclofenac.
DiflunisalThe risk or severity of adverse effects can be increased when Spirapril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Spirapril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Spirapril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Spirapril.
DiltiazemDiltiazem may increase the hypotensive activities of Spirapril.
DorzolamideDorzolamide may increase the hypotensive activities of Spirapril.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Spirapril.
DoxazosinDoxazosin may increase the hypotensive activities of Spirapril.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Spirapril.
DrospirenoneSpirapril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Droxicam.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Spirapril.
EfonidipineSpirapril may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Spirapril.
EnalaprilatSpirapril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Spirapril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Spirapril.
EpirizoleThe risk or severity of adverse effects can be increased when Spirapril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Spirapril.
EpoprostenolEpoprostenol may increase the hypotensive activities of Spirapril.
EprosartanEprosartan may increase the hypotensive activities of Spirapril.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Spirapril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Spirapril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Spirapril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Spirapril.
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Spirapril.
EtanerceptThe risk or severity of adverse effects can be increased when Spirapril is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Spirapril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Spirapril is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Spirapril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Spirapril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Spirapril.
exisulindThe risk or severity of adverse effects can be increased when Spirapril is combined with exisulind.
FelodipineFelodipine may increase the hypotensive activities of Spirapril.
FenbufenThe risk or severity of adverse effects can be increased when Spirapril is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Spirapril.
FenoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Spirapril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Spirapril is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Flurbiprofen.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Spirapril.
FosinoprilFosinopril may increase the hypotensive activities of Spirapril.
FurazolidoneFurazolidone may increase the hypotensive activities of Spirapril.
FurosemideFurosemide may increase the hypotensive activities of Spirapril.
GarlicThe serum concentration of Spirapril can be decreased when it is combined with Garlic.
GuanabenzGuanabenz may increase the hypotensive activities of Spirapril.
GuanadrelGuanadrel may increase the hypotensive activities of Spirapril.
GuanethidineGuanethidine may increase the hypotensive activities of Spirapril.
GuanfacineGuanfacine may increase the hypotensive activities of Spirapril.
HeparinHeparin may increase the hyperkalemic activities of Spirapril.
HexamethoniumSpirapril may increase the hypotensive activities of Hexamethonium.
HMPL-004The risk or severity of adverse effects can be increased when Spirapril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Spirapril.
HydralazineHydralazine may increase the hypotensive activities of Spirapril.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Spirapril.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Spirapril.
IbuprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Spirapril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Spirapril.
IcatibantThe risk or severity of adverse effects can be increased when Spirapril is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Spirapril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Spirapril.
IndapamideIndapamide may increase the hypotensive activities of Spirapril.
IndenololSpirapril may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Spirapril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Indoprofen.
IndoraminSpirapril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Spirapril.
IproniazidIproniazid may increase the hypotensive activities of Spirapril.
IrbesartanIrbesartan may increase the hypotensive activities of Spirapril.
IronThe risk or severity of adverse effects can be increased when Spirapril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Spirapril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Spirapril.
IsoxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Spirapril.
KebuzoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Spirapril is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Spirapril.
LacidipineSpirapril may increase the hypotensive activities of Lacidipine.
Lanthanum carbonateThe serum concentration of Spirapril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostLatanoprost may increase the hypotensive activities of Spirapril.
LeflunomideThe risk or severity of adverse effects can be increased when Spirapril is combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Spirapril.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Spirapril.
LisinoprilLisinopril may increase the hypotensive activities of Spirapril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Spirapril.
LofexidineSpirapril may increase the hypotensive activities of Lofexidine.
LornoxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Spirapril.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Spirapril.
LoxoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Lumiracoxib.
MacitentanSpirapril may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Spirapril is combined with Magnesium salicylate.
ManidipineSpirapril may increase the hypotensive activities of Manidipine.
MasoprocolThe risk or severity of adverse effects can be increased when Spirapril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Spirapril.
MecamylamineMecamylamine may increase the hypotensive activities of Spirapril.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Spirapril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Spirapril.
MetamizoleThe risk or severity of adverse effects can be increased when Spirapril is combined with Metamizole.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Spirapril.
MethyldopaMethyldopa may increase the hypotensive activities of Spirapril.
Methylene blueMethylene blue may increase the hypotensive activities of Spirapril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Spirapril.
MetipranololMetipranolol may increase the hypotensive activities of Spirapril.
MetolazoneMetolazone may increase the hypotensive activities of Spirapril.
MetoprololMetoprolol may increase the hypotensive activities of Spirapril.
MibefradilSpirapril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Spirapril.
MinaprineMinaprine may increase the hypotensive activities of Spirapril.
MinoxidilMinoxidil may increase the hypotensive activities of Spirapril.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Spirapril.
MoclobemideMoclobemide may increase the hypotensive activities of Spirapril.
MoexiprilMoexipril may increase the hypotensive activities of Spirapril.
MolsidomineMolsidomine may increase the hypotensive activities of Spirapril.
MoxonidineSpirapril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Nabumetone.
NadololNadolol may increase the hypotensive activities of Spirapril.
NadroparinNadroparin may increase the hyperkalemic activities of Spirapril.
NaftifineThe risk or severity of adverse effects can be increased when Spirapril is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Spirapril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Spirapril is combined with NCX 4016.
NebivololSpirapril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Spirapril.
NepafenacThe risk or severity of adverse effects can be increased when Spirapril is combined with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Spirapril.
NicardipineNicardipine may increase the hypotensive activities of Spirapril.
NicorandilNicorandil may increase the hyperkalemic activities of Spirapril.
NicorandilSpirapril may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe risk or severity of adverse effects can be increased when Spirapril is combined with Niflumic Acid.
NiguldipineSpirapril may increase the hypotensive activities of Niguldipine.
NilvadipineSpirapril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Spirapril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Spirapril.
NisoldipineNisoldipine may increase the hypotensive activities of Spirapril.
NitrendipineNitrendipine may increase the hypotensive activities of Spirapril.
NitroprussideNitroprusside may increase the hypotensive activities of Spirapril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Spirapril.
ObinutuzumabSpirapril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Spirapril.
OlmesartanOlmesartan may increase the hypotensive activities of Spirapril.
OlopatadineThe risk or severity of adverse effects can be increased when Spirapril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Spirapril is combined with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Spirapril.
OrgoteinThe risk or severity of adverse effects can be increased when Spirapril is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Spirapril is combined with Oxaprozin.
OxprenololSpirapril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Oxyphenbutazone.
ParecoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Parecoxib.
PargylineSpirapril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Spirapril.
PenbutololSpirapril may increase the hypotensive activities of Penbutolol.
PentoliniumPentolinium may increase the hypotensive activities of Spirapril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Spirapril.
PerindoprilPerindopril may increase the hypotensive activities of Spirapril.
PethidineThe risk or severity of adverse effects can be increased when Spirapril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Spirapril.
PheniprazinePheniprazine may increase the hypotensive activities of Spirapril.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Spirapril.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Spirapril.
PhentolaminePhentolamine may increase the hypotensive activities of Spirapril.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Spirapril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Spirapril.
PinacidilSpirapril may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Spirapril.
PiretanidePiretanide may increase the hypotensive activities of Spirapril.
PirfenidoneThe risk or severity of adverse effects can be increased when Spirapril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Spirapril.
PiroxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Spirapril.
PolythiazidePolythiazide may increase the hypotensive activities of Spirapril.
PrazosinPrazosin may increase the hypotensive activities of Spirapril.
PregabalinThe risk or severity of adverse effects can be increased when Spirapril is combined with Pregabalin.
PropacetamolThe risk or severity of adverse effects can be increased when Spirapril is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Spirapril.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Spirapril.
PTC299The risk or severity of adverse effects can be increased when Spirapril is combined with PTC299.
QuinaprilQuinapril may increase the hypotensive activities of Spirapril.
QuinethazoneQuinethazone may increase the hypotensive activities of Spirapril.
QuinineQuinine may increase the hypotensive activities of Spirapril.
RamiprilRamipril may increase the hypotensive activities of Spirapril.
RasagilineRasagiline may increase the hypotensive activities of Spirapril.
RemikirenRemikiren may increase the hypotensive activities of Spirapril.
RescinnamineSpirapril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Spirapril.
ResveratrolThe risk or severity of adverse effects can be increased when Spirapril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Spirapril.
RiociguatSpirapril may increase the hypotensive activities of Riociguat.
RituximabSpirapril may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Rofecoxib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Spirapril.
SacubitrilThe risk or severity of adverse effects can be increased when Spirapril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Spirapril.
SalicylamideThe risk or severity of adverse effects can be increased when Spirapril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Spirapril.
SalsalateThe risk or severity of adverse effects can be increased when Spirapril is combined with Salsalate.
SaprisartanSaprisartan may increase the hypotensive activities of Spirapril.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Spirapril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Spirapril.
SelegilineSelegiline may increase the hypotensive activities of Spirapril.
SelexipagSpirapril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Spirapril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Spirapril.
SildenafilSildenafil may increase the antihypertensive activities of Spirapril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Spirapril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Spirapril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Spirapril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Spirapril.
SitaxentanSpirapril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Spirapril is combined with Sodium aurothiomalate.
SpironolactoneSpironolactone may increase the hyperkalemic activities of Spirapril.
SRT501The risk or severity of adverse effects can be increased when Spirapril is combined with SRT501.
St. John's WortThe metabolism of Spirapril can be increased when combined with St. John's Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Spirapril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Spirapril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Spirapril.
TadalafilTadalafil may increase the antihypertensive activities of Spirapril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Spirapril.
TelmisartanTelmisartan may increase the hypotensive activities of Spirapril.
TemocaprilSpirapril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Spirapril.
TenoxicamThe risk or severity of adverse effects can be increased when Spirapril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Spirapril is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Spirapril is combined with Teriflunomide.
TerlipressinSpirapril may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Spirapril.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Spirapril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Spirapril is combined with Tiaprofenic acid.
TiboloneSpirapril may increase the hypotensive activities of Tibolone.
TicrynafenSpirapril may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Spirapril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Spirapril.
TipranavirThe serum concentration of Spirapril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Spirapril.
TolazolineTolazoline may increase the hypotensive activities of Spirapril.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Spirapril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Spirapril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Spirapril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Spirapril.
TorasemideTorasemide may increase the hypotensive activities of Spirapril.
TrandolaprilTrandolapril may increase the hypotensive activities of Spirapril.
TranilastThe risk or severity of adverse effects can be increased when Spirapril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Spirapril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Spirapril.
TravoprostTravoprost may increase the hypotensive activities of Spirapril.
TreprostinilTreprostinil may increase the hypotensive activities of Spirapril.
TriamtereneTriamterene may increase the hyperkalemic activities of Spirapril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Spirapril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Spirapril.
TrimazosinSpirapril may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Spirapril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Spirapril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Spirapril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Spirapril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Spirapril.
UnoprostoneSpirapril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Spirapril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Spirapril.
VardenafilVardenafil may increase the antihypertensive activities of Spirapril.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Spirapril.
XylometazolineSpirapril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Spirapril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Spirapril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Spirapril.
ZileutonThe risk or severity of adverse effects can be increased when Spirapril is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Spirapril is combined with Zomepirac.
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or iron supplements within 2 hours of taking this medication.
  • Herbs that may attenuate the antihypertensive effect of spirapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of spirapril.
  • Spirapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]
  2. Maul B, Krause W, Pankow K, Becker M, Gembardt F, Alenina N, Walther T, Bader M, Siems WE: Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81. [PubMed:16126915 ]
  3. Hermida RC, Ayala DE, Fontao MJ, Mojon A, Alonso I, Fernandez JR: Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol Int. 2010 May;27(3):560-74. doi: 10.3109/07420528.2010.485411. [PubMed:20524801 ]
  4. Arend U, Albrecht S, Meisel E, Schmidt J: [Influence of ACE inhibitor spirapril on left ventricular hypertrophy]. Fortschr Med Orig. 2002 Dec 5;120(4):147-50. [PubMed:12613273 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:15 / Updated on August 17, 2016 12:23